These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37549446)

  • 1. Matrix metalloproteinases are associated with brain atrophy in cognitively unimpaired individuals.
    Aksnes M; Capogna E; Vidal-Piñeiro D; Chaudhry FA; Myrstad M; Idland AV; Halaas NB; Dakhil S; Blennow K; Zetterberg H; Walhovd KB; Watne LO; Fjell AM
    Neurobiol Aging; 2023 Nov; 131():11-23. PubMed ID: 37549446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-specific associations of matrix metalloproteinases in Alzheimer's disease.
    Aksnes M; Edwin TH; Saltvedt I; Eldholm RS; Chaudhry FA; Halaas NB; Myrstad M; Watne LO; Knapskog AB
    Biol Sex Differ; 2023 May; 14(1):35. PubMed ID: 37221606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Remodeling Enzymes as Potential Fluid Biomarkers of Neurodegeneration in Alzheimer's Disease.
    Bašić J; Milošević V; Djordjević B; Stojiljković V; Živanović M; Stefanović N; Aracki Trenkić A; Stojanov D; Jevtović Stoimenov T; Stojanović I
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.
    Xing Y; Shepherd N; Lan J; Li W; Rane S; Gupta SK; Zhang S; Dong J; Yu Q
    Brain Behav Immun; 2017 Oct; 65():161-172. PubMed ID: 28487203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease.
    Stomrud E; Björkqvist M; Janciauskiene S; Minthon L; Hansson O
    Alzheimers Res Ther; 2010 Jun; 2(3):20. PubMed ID: 20576109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy.
    Vervuurt M; de Kort AM; Jäkel L; Kersten I; Abdo WF; Schreuder FHBM; Rasing I; Terwindt GM; Wermer MJH; Greenberg SM; Klijn CJM; Kuiperij HB; Verbeek MM
    Alzheimers Res Ther; 2023 Jan; 15(1):26. PubMed ID: 36717932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults.
    Vidal-Piñeiro D; Sørensen Ø; Blennow K; Capogna E; Halaas NB; Idland AV; Mowinckel AM; Pereira JB; Watne LO; Zetterberg H; Walhovd KB; Fjell AM;
    Neurobiol Aging; 2022 Aug; 116():80-91. PubMed ID: 35584575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in metalloproteinases and their tissue inhibitors in the cerebrospinal fluid are associated with delirium.
    Aksnes M; Schibstad MH; Chaudhry FA; Neerland BE; Caplan G; Saltvedt I; Eldholm RS; Myrstad M; Edwin TH; Persson K; Idland AV; Pollmann CT; Olsen RB; Wyller TB; Zetterberg H; Cunningham E; Watne LO
    Commun Med (Lond); 2024 Jun; 4(1):124. PubMed ID: 38937571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Kulczyńska A; Koper OM; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2014; 40(2):351-7. PubMed ID: 24448781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds.
    Duits FH; Hernandez-Guillamon M; Montaner J; Goos JD; Montañola A; Wattjes MP; Barkhof F; Scheltens P; Teunissen CE; van der Flier WM
    J Alzheimers Dis; 2015; 48(3):711-20. PubMed ID: 26402072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
    Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
    J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
    Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
    Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid.
    Kolb SA; Lahrtz F; Paul R; Leppert D; Nadal D; Pfister HW; Fontana A
    J Neuroimmunol; 1998 Apr; 84(2):143-50. PubMed ID: 9628456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Function in Patients with Myocarditis.
    Kobusiak-Prokopowicz M; Kaaz K; Marciniak D; Karolko B; Mysiak A
    Kidney Blood Press Res; 2021; 46(6):749-757. PubMed ID: 34801997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
    JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of neuroinflammatory IL-6 and IL-8 with brain atrophy, memory decline, and core AD biomarkers - in cognitively unimpaired older adults.
    Capogna E; Watne LO; Sørensen Ø; Guichelaar CJ; Idland AV; Halaas NB; Blennow K; Zetterberg H; Walhovd KB; Fjell AM; Vidal-Piñeiro D
    Brain Behav Immun; 2023 Oct; 113():56-65. PubMed ID: 37400002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.